Dr. Reza Mehrazin is Associate Professor of Urology, Icahn School of Medicine at Mount Sinai. Dr. Mehrazin joined the surgical staff at Mount Sinai School of Medicine after completing a two-year Society of Urologic Oncology (SUO) accredited fellowship at a highly prestigious National Cancer Institute (NCI) designated cancer center, Fox Chase Cancer Center. Prior to his fellowship, he completed his general surgery internship and urology residency at University of Tennessee Health Science Center.
Dr. Mehrazin’s clinical expertise is in open, laparoscopic, and robotic surgical techniques for the treatment of various urologic cancers, which allows him to tailor a specific treatment plan based on individual patient need and preferences. He is one of the few urologists in the region who has extensive training and certified in performing minimally invasive organ preserving and reconstructive techniques to preserve function and quality of life for patients with kidney cancer and bladder cancer. He performs both robotic (using da Vinci® technology) and open cystectomies with continent urinary diversion (new bladder), nephron-sparing (kidney preserving) partial nephrectomy, nerve-sparing prostatectomy, partial or total adrenalectomy, retroperitoneal lymph node dissection for testicular cancer, and endoscopic nephron-sparing management of patients with upper tract urothelial carcinomas. He also has a special clinical interest in the management of patients with metastatic and advanced kidney cancer with tumors extending into the surrounding organs or major vessels, as well as salvage bladder surgeries following radiation therapy.
His research interests revolve around novel clinical and surgical treatment of kidney and bladder cancer. Over 250 of his abstracts have been presented at international, national, and regional scientific meetings. He has authored and co-authored over 100 scientific papers which are published or currently in press in major, high impact journals, such as The Journal of Urology, European Urology, and Urologic Oncology. His published work on the active surveillance of small renal masses (greater than 4 cm in size)is the largest single-center series reported to date.
In addition he has authored several text book chapters on kidney, prostate, and adrenal tumors. He has also served as a member of editorial board for several journals.
He takes a multi-disciplinary approach and works closely with Medical Oncology and Radiation Oncology physicians at Mount Sinai Health Care System to deliver comprehensive care and support for each patient.
He is a member of the American Urological Association, Society of Urologic Oncology and American Society of Clinical Oncology.
BLADDER CANCER Dr. Mehrazin speaks about Robotic Cystectomy http://blog.mountsinai.org/blog/robotic-cystectomy-vs-open-cystectomy/
KIDNEYCANCER Dr. Menrazin comments discusses his research about close monitoring of renal tumors https://www.mountsinai.org/about/newsroom/2015/close-monitoring-of-renal-tumors-may-provide-alternative-to-surgery
Dr. Mehrazin discusses kidney cancer signs and symptoms of new advances in treatment http://www.nydailynews.com/life-style/daily-checkup-kidney-cancer-attention-article-1.2385577
Dr. Mehrazin's Patient Stories:
- Mount Sinai Beth Israel
- Mount Sinai Queens
- The Mount Sinai Hospital
- New York Eye and Ear Infirmary of Mount Sinai
- Mount Sinai Morningside and Mount Sinai West
Anti-Tumor Therapy, Cancer, Imaging, Kidney, Prostate, Robotic Surgery, Technology & Innovation